Generic Aloxi launches from Dr. Reddy’s
Dr. Reddy’s Laboratories has introduced its generic Aloxi (palonosetron hydrochloride injection). The drug, which had been previously approved by the Food and Drug Administration, is indicated to treat chemotherapy-induced nausea and vomiting in adults.
Dr. Reddy’s generic Aloxi will be available in 0.25 mg/5 ml dosage strength. It will be packaged in a carton containing one single-dose vial. The drug’s market size is roughly $446 million for the 12 months ended January 2018, according to IQVIA data.
Teva launches Lialda generic
Teva has introduced its Lialda generic (mesalamine delayed-release tablets). The drug is indicated to treat mild-to-moderate ulcerative colitis.
“The launch of mesalamine is a significant addition to Teva’s generic portfolio,” Teva executive vice president and head of North American Commercial Brendan O’Grady said. “With more than a million people in the U.S. estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers.”
Teva’s Lialda generic will be available in 1.2-g dosage strength. The product’s market size was roughly $1.11 billion for the 12 months ended January 2018, according to IQVIA data.
Lupin intros generic Lodosyn
Lupin has launched its generic of Lodosyn (carbidopa) tablets. The company had previously received approval from the Food and Drug Administration for the generic, which is indicated to treat symptoms associated with Parkinson’s disease alongside carbidopa-levodopa or levodopa.
Lupin’s generic Lodosyn will be available in 25-mg dosage strength. The product has a market size of roughly $17.4 million for the 12 months ended January 2018, according to IQVIA data.